Incidences of cardiovascular and cognitive diseases are rising rapidly among an ageing global population. SunWay Biotech's supplement could hold the key to healthy, happier lives for senior citizens.
According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, while an estimated 50 million people worldwide were living with dementia in 2017. This latter figure is expected to increase rapidly, reaching 75 million in 2030.
New food supplement ANKASCIN 568-R answers the call for a safe and effective active compound that benefits heart and cognitive health. It is an extract of fermented products of Monascus purpureus NTU 568.
Its positive effects come from two high levels of active compounds monascin (MS) and ankaflavin (AK). These yellow pigment metabolites are produced naturally from SunWay Biotech's patented solid fermentation technique. ANKASCIN 568-R has been supported by more than 120 SCI publications, and its research and development team has dedicated years to doing clinical trials verifying their effects on blood lipid (cholesterol), blood glucose, blood pressure regulation, and memory and cognitive health improvement.
Although the cause of Alzheimer's disease still isn't clear, a lot of research indicates that high cholesterol and blood pressure could be major contributory factors. Through animal tests observing rats with high-fat diets and aluminium-induced Alzheimer's, researchers found that ANKASCIN 568-R significantly reduced key risk factors (amyloid-beta 1-42, amyloid-beta 1-40, pTau) in the hippocampus. Positive effects have also been observed in pilot clinical trials.
ANKASCIN 568-R, which has no side effects, has completed a 90-day oral-toxicity study, and completed in-vitro mammalian chromosomal aberration assay, micronucleus assay and the Ames test to become an FDA-approved New Dietary Ingredient (NDI). With heart disease and dementia on the rise worldwide, the market for such an ingredient is potentially enormous.